LENZ and Everest Enter Asset Purchase Agreement for VIZZ in Greater China
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- Asset Purchase Agreement: LENZ Therapeutics has signed an asset purchase agreement with Everest Medicines, granting Everest the rights to develop, manufacture, and commercialize VIZZ (LNZ100) in Greater China, significantly enhancing LENZ's market penetration in the region.
- Regulatory Milestone Revenue: LENZ stands to receive up to $85 million in regulatory and sales milestone payments from this transaction, along with tiered mid-single-digit to low double-digit royalties on net sales in Greater China, further strengthening the company's financial stability.
- Market Demand Opportunity: As the population of presbyopia patients continues to grow, LNZ100 offers a non-invasive treatment option that addresses the urgent market need for innovative ophthalmic therapies, expected to drive the company's strategic development in the ophthalmology sector.
- Collaborative Outlook: The partnership between LENZ and Everest will accelerate the regulatory approval and commercialization of LNZ100 in China, anticipated to provide a transformative treatment option for millions of presbyopia patients, thereby solidifying LENZ's competitive position in the global market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LENZ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LENZ
Wall Street analysts forecast LENZ stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.200
Low
52.00
Averages
57.50
High
62.00
Current: 7.200
Low
52.00
Averages
57.50
High
62.00
About LENZ
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
LENZ and Everest Enter Asset Purchase Agreement for VIZZ in Greater China
- Asset Purchase Agreement: LENZ Therapeutics has signed an asset purchase agreement with Everest Medicines, granting Everest the rights to develop, manufacture, and commercialize VIZZ (LNZ100) in Greater China, significantly enhancing LENZ's market penetration in the region.
- Regulatory Milestone Revenue: LENZ stands to receive up to $85 million in regulatory and sales milestone payments from this transaction, along with tiered mid-single-digit to low double-digit royalties on net sales in Greater China, further strengthening the company's financial stability.
- Market Demand Opportunity: As the population of presbyopia patients continues to grow, LNZ100 offers a non-invasive treatment option that addresses the urgent market need for innovative ophthalmic therapies, expected to drive the company's strategic development in the ophthalmology sector.
- Collaborative Outlook: The partnership between LENZ and Everest will accelerate the regulatory approval and commercialization of LNZ100 in China, anticipated to provide a transformative treatment option for millions of presbyopia patients, thereby solidifying LENZ's competitive position in the global market.
See More
LENZ Therapeutics Q1 2026 Earnings Call Insights
- Performance Overview: LENZ Therapeutics delivered approximately 25,000 paid and filled prescriptions in Q1 2026, generating $1.9 million in net revenue, including $1.7 million from product sales, indicating a steady performance despite slower-than-expected new patient adoption.
- Prescription Growth: The number of prescriptions for VIZZ increased by 19% compared to Q4, with each prescriber generating roughly 30% more scripts than VUITY, suggesting a growing acceptance of the product in the market and potential for further market share expansion.
- Sales Team Expansion: The company has established a base of over 10,000 unique prescribers, and the field sales team is expected to be fully deployed by the end of this quarter, reaching approximately 15,000 targeted eye care professionals, which will enhance market responsiveness and drive sales growth.
- Financial Position: SG&A expenses rose to $45 million in Q1, with a net cash burn of approximately $34 million; however, the company ended the quarter with about $258.4 million in cash and cash equivalents, demonstrating a degree of financial resilience amidst cost pressures.
See More
LENZ Therapeutics Q1 Earnings Announcement Scheduled
- Earnings Release Date: LENZ Therapeutics is set to announce its Q1 earnings on May 11th after market close, with a consensus EPS estimate of -$1.07, reflecting a concerning 101.9% year-over-year decline, indicating significant market challenges.
- Revenue Expectations Decline: The revenue estimate for Q1 stands at $1.76 million, with no upward revisions in the last three months and four downward adjustments, highlighting weak market demand and sales difficulties faced by the company.
- Earnings Estimate Volatility: Over the past three months, EPS estimates have seen one upward revision and three downward revisions, suggesting a lack of confidence among analysts regarding the company's profitability, which could influence investor decisions.
- Market Reaction: Despite the negative outlook, LENZ Therapeutics is still considered a speculative buy, as market interest in its future growth strategy may lead to stock price fluctuations.
See More
Lenz Therapeutics Shares Drop Nearly 20% Following Earnings Miss
- Earnings Miss: Lenz Therapeutics reported fourth-quarter revenue of $1.59 million for fiscal 2025, significantly below analysts' expectations of $3.1 million, leading to a nearly 20% drop in stock price this week as investor sentiment soured.
- Widening Net Loss: The company's GAAP net loss deepened to $35.9 million ($1.16 per share), compared to a loss of $12.7 million in the same quarter last year, highlighting the financial strain of commercialization costs.
- Price Target Cuts: Citigroup and Bank of America both slashed their price targets for Lenz from $52 and $35 to $26 and $29 respectively, indicating growing concerns about the company's future profitability.
- Market Potential Assessment: Despite short-term challenges, analysts believe Lenz's VIZZ product has the potential to attract a large patient base, particularly for treating presbyopia, and suggest investors give the company more time to evaluate its marketing effectiveness.
See More
LENZ THERAPEUTICS INC: BOFA GLOBAL RESEARCH LOWERS PRICE TARGET FROM $35 TO $29
- Price Reduction Announcement: Lenz Therapeutics has announced a price cut for its product, reducing the price from $35 to $29.
- Impact on Global Research: This price adjustment is part of a broader strategy to enhance accessibility and support global research initiatives.
See More
LENZ Therapeutics Reports Strong Q4 2025 Earnings and Growth Prospects
- Product Sales Success: LENZ's VIZZ product has sold over 45,000 boxes in its early launch phase, prescribed by more than 10,000 eye care professionals, indicating strong market acceptance that exceeds recent eye care product launches.
- Strong Financial Position: As of the end of 2025, the company reported over $292.3 million in cash and cash equivalents, remaining debt-free, which supports future market expansion and product promotion efforts.
- Sales Team Expansion: The company plans to expand its sales force to 117 representatives to increase call frequency with existing prescribers and broaden the number of physicians covered, thereby driving market penetration of the product.
- Increased Market Awareness: Brand awareness among eye care professionals has reached 98%, with expectations to exceed 10,000 prescribing doctors by the end of Q1, indicating significant progress in consumer education and market promotion efforts.
See More
LENZ and Everest Enter Asset Purchase Agreement for VIZZ in Greater China
- Asset Purchase Agreement: LENZ Therapeutics has signed an asset purchase agreement with Everest Medicines, granting Everest the rights to develop, manufacture, and commercialize VIZZ (LNZ100) in Greater China, significantly enhancing LENZ's market penetration in the region.
- Regulatory Milestone Revenue: LENZ stands to receive up to $85 million in regulatory and sales milestone payments from this transaction, along with tiered mid-single-digit to low double-digit royalties on net sales in Greater China, further strengthening the company's financial stability.
- Market Demand Opportunity: As the population of presbyopia patients continues to grow, LNZ100 offers a non-invasive treatment option that addresses the urgent market need for innovative ophthalmic therapies, expected to drive the company's strategic development in the ophthalmology sector.
- Collaborative Outlook: The partnership between LENZ and Everest will accelerate the regulatory approval and commercialization of LNZ100 in China, anticipated to provide a transformative treatment option for millions of presbyopia patients, thereby solidifying LENZ's competitive position in the global market.
See More
LENZ Therapeutics Q1 2026 Earnings Call Insights
- Performance Overview: LENZ Therapeutics delivered approximately 25,000 paid and filled prescriptions in Q1 2026, generating $1.9 million in net revenue, including $1.7 million from product sales, indicating a steady performance despite slower-than-expected new patient adoption.
- Prescription Growth: The number of prescriptions for VIZZ increased by 19% compared to Q4, with each prescriber generating roughly 30% more scripts than VUITY, suggesting a growing acceptance of the product in the market and potential for further market share expansion.
- Sales Team Expansion: The company has established a base of over 10,000 unique prescribers, and the field sales team is expected to be fully deployed by the end of this quarter, reaching approximately 15,000 targeted eye care professionals, which will enhance market responsiveness and drive sales growth.
- Financial Position: SG&A expenses rose to $45 million in Q1, with a net cash burn of approximately $34 million; however, the company ended the quarter with about $258.4 million in cash and cash equivalents, demonstrating a degree of financial resilience amidst cost pressures.
See More
LENZ Therapeutics Q1 Earnings Announcement Scheduled
- Earnings Release Date: LENZ Therapeutics is set to announce its Q1 earnings on May 11th after market close, with a consensus EPS estimate of -$1.07, reflecting a concerning 101.9% year-over-year decline, indicating significant market challenges.
- Revenue Expectations Decline: The revenue estimate for Q1 stands at $1.76 million, with no upward revisions in the last three months and four downward adjustments, highlighting weak market demand and sales difficulties faced by the company.
- Earnings Estimate Volatility: Over the past three months, EPS estimates have seen one upward revision and three downward revisions, suggesting a lack of confidence among analysts regarding the company's profitability, which could influence investor decisions.
- Market Reaction: Despite the negative outlook, LENZ Therapeutics is still considered a speculative buy, as market interest in its future growth strategy may lead to stock price fluctuations.
See More
Lenz Therapeutics Shares Drop Nearly 20% Following Earnings Miss
- Earnings Miss: Lenz Therapeutics reported fourth-quarter revenue of $1.59 million for fiscal 2025, significantly below analysts' expectations of $3.1 million, leading to a nearly 20% drop in stock price this week as investor sentiment soured.
- Widening Net Loss: The company's GAAP net loss deepened to $35.9 million ($1.16 per share), compared to a loss of $12.7 million in the same quarter last year, highlighting the financial strain of commercialization costs.
- Price Target Cuts: Citigroup and Bank of America both slashed their price targets for Lenz from $52 and $35 to $26 and $29 respectively, indicating growing concerns about the company's future profitability.
- Market Potential Assessment: Despite short-term challenges, analysts believe Lenz's VIZZ product has the potential to attract a large patient base, particularly for treating presbyopia, and suggest investors give the company more time to evaluate its marketing effectiveness.
See More
LENZ THERAPEUTICS INC: BOFA GLOBAL RESEARCH LOWERS PRICE TARGET FROM $35 TO $29
- Price Reduction Announcement: Lenz Therapeutics has announced a price cut for its product, reducing the price from $35 to $29.
- Impact on Global Research: This price adjustment is part of a broader strategy to enhance accessibility and support global research initiatives.
See More
LENZ Therapeutics Reports Strong Q4 2025 Earnings and Growth Prospects
- Product Sales Success: LENZ's VIZZ product has sold over 45,000 boxes in its early launch phase, prescribed by more than 10,000 eye care professionals, indicating strong market acceptance that exceeds recent eye care product launches.
- Strong Financial Position: As of the end of 2025, the company reported over $292.3 million in cash and cash equivalents, remaining debt-free, which supports future market expansion and product promotion efforts.
- Sales Team Expansion: The company plans to expand its sales force to 117 representatives to increase call frequency with existing prescribers and broaden the number of physicians covered, thereby driving market penetration of the product.
- Increased Market Awareness: Brand awareness among eye care professionals has reached 98%, with expectations to exceed 10,000 prescribing doctors by the end of Q1, indicating significant progress in consumer education and market promotion efforts.
See More
